Danaher Corporation (DHR)
NYSE: DHR · Real-Time Price · USD
211.80
+7.90 (3.87%)
At close: Aug 22, 2025, 4:00 PM
211.60
-0.20 (-0.09%)
After-hours: Aug 22, 2025, 7:36 PM EDT
Danaher Revenue
Danaher had revenue of $5.94B in the quarter ending June 27, 2025, with 3.36% growth. This brings the company's revenue in the last twelve months to $24.01B, up 1.89% year-over-year. In the year 2024, Danaher had annual revenue of $23.88B, down -0.06%.
Revenue (ttm)
$24.01B
Revenue Growth
+1.89%
P/S Ratio
6.35
Revenue / Employee
$381,159
Employees
63,000
Market Cap
151.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.88B | -15.00M | -0.06% |
| Dec 31, 2023 | 23.89B | -2.75B | -10.33% |
| Dec 31, 2022 | 26.64B | 1.84B | 7.42% |
| Dec 31, 2021 | 24.80B | 2.52B | 11.30% |
| Dec 31, 2020 | 22.28B | 4.37B | 24.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
DHR News
- 15 days ago - Analysts' Top S&P 500 Stocks to Buy Now - Kiplinger
- 18 days ago - Danaher Stock Closes Near Day's High After Key Trading Signal - Benzinga
- 22 days ago - Danaher Appoints Jonathan Leiken as General Counsel - PRNewsWire
- 4 weeks ago - Danaher Q2 2025 Update - Seeking Alpha
- 4 weeks ago - Danaher Stock: Attractively Valued And Poised For Growth Acceleration - Seeking Alpha
- 4 weeks ago - Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Danaher lifts annual profit view on strength in diagnostics, names new CFO - Reuters
- 4 weeks ago - Danaher Announces Transition Plan for Chief Financial Officer - PRNewsWire